Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday
Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with several rating upgrades and downgrades.
Stocks · News reference
Allarity Therapeutics Announces SPAC Allarity Acquisition Corp. Filed Form S-1 For $100M IPO, Up To $115M With Over-Allotment; Sponsor Subsidiary To Own About 25%
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Allarity Therapeutics, Inc. (ALLR)
Filed: 2026-09-16 AccNo: 0001213900-26-100350 Size: 218 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $11
Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $10.25 to $11.